Effect of nesiritide on length of hospital stay in decompensated heart failure  by Chang, Richard et al.
JACC March 19,2003 
9q31 is responsible. Although cardiac mvolvament is common and develops with age in 
patients with Duchenne and Becker-type muscular dystrophy caused by dystrophin gene 
mutation, little is known about cardiac involvement in patients with FCMD. This study 
evaluated if cardiac involvement exists in pabents with FCMD. Methods: We evaluated 
left ventricular (LV) function using M-mode and Doppler echocardiography in 35 pabents 
with FCMD. The age ranged from 6 months to 31 years (mean: 11 yrs). A total of 53 
recordings were analysed. LV systolic function parameters included end-diastolic dimen- 
sion, shortening fraction, septal and posterior wall thickness, and mean velocity of cir- 
cumferencial fiber shortening (mVcf) and end-systolic wall stress (ESWS) relationshlp. 
Parameters of LV diastolic function included peak early and late inflow velocity (E and A, 
respectively) and EIA ratio. Results: LV end-diastolic dimension increased to more than 
2SD from normal value in 3 patients (9%). LV shortening fraction decreased to less than 
0.25 and mVcf-ESWS relationship showed decreased mVcf in 9 patients (26%). Df 11 
patients z-15 years of age, 8 patients (73%) showed decreased LV systolic function. Sig- 
nificant correlation between age and LV shortening fraction was observed; LV shortening 
fraction decreased with age. Two patients died of heart failure at 16 and 17 years of age, 
respectively, and histology confirmed the presence of myocardial fibrosis. E/A ratio was 
ratio was < 1 in 31% of patients. No patients showed increased LV wall thickness or con- 
duction abnormality on ECG. Conclusion: LV systolic and diastolic dysfunction are com- 
mon in FCMD and become evident in older children > 15 years of age. 
1062-87 Prevalence and Prognostic Implications of Pulmonary 
Hypertension in Patients With Surgically Proven 
Constrictive Pericarditis 
Deepak R. Talreia, Jae K. Oh, Lieng H. Ling, Hartzell V. Schaff, Mayo Clinic, Rochester, 
MN 
Background: Normal pulmonary artery systolic pressure (PASP) has traditionally been 
used to distinguish constrictive pericarditis (CP) from restrictive myocardial diseases 
@MD), but this criterion has poor specificity. TO better understand the prevalence and 
prognostic implications of pulmonary hypertension in CP, we reviewed a consecutive 
series of patients with proven constriction. 
Methods: Case histories of all patients with the diagnosis of CP confirmed at surgery or 
autopsy at the Mayo Clinic from January 1985 through June 1997 (n=224) ware 
reviewed. Among these patients, 161 had PASP determined by echocardiography and/or 
cardiac catheterization. Thirty-two patients with conflicting data by both techniques were 
excluded. The remaining patients were divided into two groups: group 1 had PASP<BO 
mmHg (n=l03), and group 2 had elevated PASPx50 mmHg (n=26). 
Results: Pulmonary hypertension (PASP>=50 mmHg) was seen in 20%. Among group 2 
patients, mean PASP by echo was 58 mmHg (range, 50.85) and by cardiac catheteriza- 
tion, 59 mmHg (range, 50-85). Comparison of etiologies between groups showed that 
prior cardiovascular surgery (18% vs 38%) and irradiation (13% vs 19%) were more com- 
mon in group 2, while idiopathic (likely viral) etiology was more common in group 1 (29% 
YS 15%). Comparing the patients in group 1 with those in group 2, there was no differ- 
ence in LVEF (56% vs 58%). or frequency of significant MR (2% vs 0%) or TR (5% vs 
4%). Perioperative (30 day) mortality was significantly higher in group 2 (19% vs. 5%). Of 
the late survivors in whom functional class could be determined at 12 to 60 months, func- 
tional status had improved in both groups as determined by statistical matched-pairs t- 
testmg; group 1 NYHA class improved from 2.8 to 1.5 (peO.0001) and in group 2 from 3.4 
to 2.7 (p-zO.04). Furthermore, after pericardiectomy, PASP decreased significantly in 
group 2 patients (average PASP of 61 mmHg preoperatively vs. 46 mmHg postopera- 
tively, pcO.004). 
Conclusion: PASP is elevated in 20 % of patients with surgically proven CP. Patients with 
elevated PASP have higher perioperative mortality, but those who survive pericardiec- 
tomy show clinical improvement as do their counterparts with normal PASP. 
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dlcts prognosis. OVI can be measured rapidly and inexpensively I” large numbers of 
patients. 
1062-88 A Novel Periodic Breathing Index in Awake Patients 
With Heart Failure Predicts Prognosis 
Robert L. Bard, John M. Nick@ University of Michigan, Ann Arbor, Ml 
Background: The presence of periodic breathing (PB) in awake patients has not been 
clearly established. We hypothesized that PB could be assessed with a quantitative 
mdex that would predict patient prognosis in awake heart failure (HF) patients. 
Methods: We assessed PB in 422 HF patients. Resting gas exchange was measured 
after 1 mm of rest in Fowler’s position. PB was quantified by the oscillatory ventilation 
index (OVI), defined as the maximal sequential difference between peak and nadir venti- 
lation divided by the average ventilation durmg 1 min. Patients were followed for up to 5 
yrs, average 2.6 yrs. OVI was compared to other potential covariate predictors of survival 
including age, gender, e]ection fraction (EF), blood pressure, heart rate, serum sodium, 
QRS prolongation, etiology, and peak oxygen consumption (peak V02). 
Results: Forty-four patients had severe PB defined as an OVI > 30%. These patients 
ware matched to 44 comparison controls without PB according to peak VQ. age, gen- 
der, and ebology. PB patients had greater mortality rates than controls by Kaplan-Meier 
survival analysis, p=O.O04. Usmg a Cox regression model for all 88 patients, only the 
covariates OVI, EF, and serum sodium predicted survival. OVI quartile also predicted 
mortality (p= 0.002) with a relatwe mortality risk of 1.9 par quartile increment. 
Conclusion: The OVI. a novel mdex of PB in awake patients wth HF, accurately pra- 
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1085-70 la There Risk Associated With the Use of Nesiritide for 
Acute Heart Failure? 
Jonathan Sackner-Bernstein Marcin Kowalski, Marshal Fox, St. Luke&Roosevelt 
Hospital Center, New York, NY 
Background Nesiritide (NES) improves symptoms in patients with acutely decompen- 
sated heart failure compared to placebo. Although safer than dobutamine, its risk relative 
to diuretic and vasodilator drug (DVD) therapy is unclear. We repolt the 30 day (30d) and 
6 month (6m) risks of death with NES compared to DVD. Methods Two trials were iden- 
tified comparing NES to DVD, VMAC and Proaction, and survival rates were obtained 
from the FDA website and from presentations to investor conferences. Odds ratio (OR) 
using random effects model was calculated for m&.-analysis of risk of death within 306 
using Mantel-Haenszel test applied to data from these 2 studies. 6m risk was determined 
from Kaplan-M&r analysis using intention-to-treat principle and grouping pabents by the 
3 randomized treatment groups (neither of which were done m VMAC analysis) using a 
Pet0 and Pet& generalized Wilcoxon test. Results. 735 patients were included in the 
analysis of 30d risk and 498 in that for 6m risk. NES trended towards higher risk by 30d 
(crude mortality 7.2% vs. 3.6% OR = 1.97, 95% Cl of 0.98-3.95, p= 0.057). At 6m, by 
intent to treat analysis NES trended toward higher risk of death (p = 0.068, crude mortal- 
ity rates of 33%, 22%, and 20% for NES adjustable dose, NES fixed dose and nitroglyc- 
erin (DVD) respectively. 
Kaplan-Meier analysis comparing NES adjustable dose, NES fixed dose and all NES 
treated patients to DVD at 6m revealed OR of 1.97 (1.06-3.67), 1.12 (0.71-1.78) and 1.27 
(0.83-1.96), log rank p=O.OlE. 0.49, and 0.17, respectively. Conclusions. Compared to 
DVD, NES appears to be a higher risk treatment for acutely decompensated heart failure. 
Although effective at reducing symptoms compared to placebo, the modest acute clinical 
benefit compared to DVD (when including IV nitroglycerin) coupled with possible long- 
term risk need to be considered prior to widespread cllnical use. A prospective mortality 
trial is necessary. Analysis of public domain information available from the FDA and from 
the investment community can provide added insight about the risk:benefit ratio of medi- 
cal treatments. 
1085-71 Effect of Nesiritide on Length of Hospital Stay in 
Decompensated Heart Failure 
Richard Chanq, Wafaa A. Elatre, J. Thomas Heywood, Loma Linda Unwersity. Loma 
Linda, CA 
Background: Nesiritide (Nes) has been shown to rapidly improve hemodynamics and 
decrease symptoms in patients with heart failure (HF) when added to cOnventional ther- 
apy. However Nes is more expensive than diuretics; it is unclear if accelerated symptom- 
atic improvement translates mto reduced length of stay (LOS) without compromising 
renal function. 
Objective: To determine the effect of Nes on LOS and renal function. Methods: Demo- 
araphics. concurrent medications and lab values were retrospectivelv evaluated for 130 _ , 
consecutwe patients discharged from the Coronary Care Unit with a diagnow of HF from 
Julv 2001 -Julv 2002. Analvsis: Univariate analvses were done to compare 58 Patients 
(Nds Group) who intially received Nes for a ma& duration of 2.2 days {median 1.7) with 
72 patients who did not (NON Nes Group). Results: The Nes group had a lower baseline 
EF. SP, higher creatinine and longer QRS (see Table). Despite these parameters indicat- 
ing that the Nes patients were more III, the LOS in the NES group was significantly 
shorter compared to the non-NES group (p=O.O02). Multiple linear regression analysis 
Indicated that LOS was significantly related to NES usage (p=O.OOl). 
Subspecialty 
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Nes Group Non Nes Group P-value 
(i.e. beta blockers), and SP has been prescribed to a broad population of HF patients. 
We sought to define the incidence of HK and RI with SP therapy in HF patients in our 
clinicat practice. 
Methods: We studied clinical data from 926 consecutive patients with HF started on SP 
from 1996 to 2002. We compared baseline characteristics, medications & laboratory data 
at selected time points on 126 randomly selected controls and 67 (7.2%) cases (SP was 
stopped due to HK - >B.OmEqlL or RI - creatinine >= 2.5 mg/dL). Between group compar- 
ison was done using non-parametric Mann-Whitney tests. Multivariate logistic regression 
was performed to Identify independent predictors of HK and RI. Data are expressed as 
mean + s.d., p value. 
Results: Analysis of the study subjects (age 59 f 13, female 37%, ejectlon fraction 0.25 
* 0.13, angiotensin converting enzyme inhibitors 94%, beta blockers 64%) revealed that, 
compared to controls, cases were older (63 f 10 vs 57 * 14, 0.002), had lower New York 
Heart Association class (2.4 * 0.5 vs 2.6 t 0.7, 0.04), had higher baseline serum glucose 
(144 i 72 vs 124 + 63 mg/dL, O.Ol), potassium (4.4 kO.4 vs 4.3 t 0.5 mEq/L, 0.02), and 
creatinine (1.3 * 0.3 vs 1.2 * 0.3 mg/dL, 0.02). and were more likely to be treated with 
beta blockers (96% vs 79%, 0.002) and thiazide diuretics (43% vs 29%, 0.04). Indepen- 
dent predictors of HK included age, beta blocker use, diabetes and baseline potassium 
dosage, while independent predictors of RI included thiazide diuretic use and baseline 
creatinine. 
(w56) 
Baseline parameters 
Age (years) 56 
Gender-Male 41(72%) 
Systolic pressure (.SP)(mm Hg) 115 
Sodium (mEqlL) 137 
Blood Urea Nitrogen (BUN) 50 
Serum Creatinine (mg/dL) 1.97 
Ejection Fraction 16 
QRS duration 152 
Using ACEI or ARB (%) 93% 
Using Beta Blockers (%) 59% 
Results (admission to discharge) 
Change in BUN -1.9 
Change in Creatinine -0.11 
Change in Weight (pounds) 10.5 
LOS (days) 2.67 
(n=72) 
66 0.07 
36(55%) 0.04 
126 0.011 
137 0.759 
40 0.067 
1.57 0.023 
24 0.023 
130 0.005 
66.5% 0.54 
69% 0.45 
-1.4 0.643 
-0.01 0.636 
11 0.740 
3.79 0.002 
Conclusion: Although the Nes Group was more ill, LOS was significantly shorter for this 
group. In addition use of Nes resulted in no significant change in renal function, same 
decrease in weight in a shorter period of time. Thus, use of Nes as initial therapy may 
allow more rapid discharge of patients without compromising renal function 
1085-72 Discordant Prescription of Guideline-Directed Therapy 
for Heart Failure Between Subspecialties of Cardiology 
Marv N. Walsh, Cynthia D. Adams, The Care Group, LLC, Indianapolis, IN 
Background: The updated ACCIAHA guidelines for management of heart failure (HF) 
clearly describe the mortality and morbidity benefits associated with beta blockers (BB) 
and ACE inhibitors in HF. In spite of wide dissemination of these data, variability in 
adherence likely exists. The purpose of this study was to examine practice patterns 
among cardiologists with regard to prescription of BB and either ACE inhibitors or angio- 
tensin II receptor blockers (ACE) in HF patients (pts). 
Methods: The electronic medical record (EMR) at a large, urban cardiology practice was 
queried to report BB and ACE use in pts with diagnoses of HF or cardiomyopathy. The 
ability of the EMR to select pts by diagnosis, sort by physician, and identify medications, 
enabled examination of variability in prescribing practices. 
Results: 1956 pts with appropriate diagnoses were examined. 57% were prescribed BB; 
75% ACE; and 46% both. The range of BB use among individual physicians was 20. 
94%; ACE 44-93%: and both 14.67%. Comparison between subspecialists is outlined 
below. 
HF 
Non-invasive 
69% 
Invsslve 
Interventional 
Electrophysiologists 
BB 
ACE 
63% 
43% 
71% 
55% 
71% 
50% 
71% 
57% 
BB+ACE 
61% 
32% 
47% 
41% 
Conclusion: Wide variation was found in the prescription of BB and ACE in HF pts 
among cardiology subspecialties. HF specialists most closely adhered to guidelines. 
Most notably, BB plus ACE was prescribed in 61% of pts by HF specialists, compared to 
only 3247% by other cardiologists. These data clearly show the need for increased 
awareness of guideline-directed therapy, even among cardiologists. Such feedback may 
enhance appropriate use of proven therapies. 
1085-73 Splronolactone Induced Renal Impairment and 
Hyperkalemia in Patients With Heart Failure: Can We 
Predict These Side Effects? 
Kamala P. Tamirisa, Keith D. Aaronson, Robert J. Cody, Todd M. Koellin$. University of 
Michigan, Ann Arbor, Ml 
Background: Clinical trials evaluating the effects of spironolactone (SP) in heart failure 
(HF) reported that 2% of patients required discontinuation of SP due to hyperkalemia 
(HK) or renal impairment (RI). Medical therapy for HF has evolved since these studies 
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Conclusions: SP induced HK and RI are more common in our clinical experience than 
reported previously. This difference may be partially explained by the frequent use of 
beta blockers to treat HF and concomitant medications and comorbidities. Redoubled 
efforts are necessary to protect patients against these infrequent yet serious side effects 
of SP. 
1085-74 Do Patients Necessarily Have to Start With an 
Angiotension Converting Enzyme Inhibitor In the 
Treatment of Heart Failure? Results of the CARMEN 
(Carvediloi ACE Inhibitor Remodeling Mild CHF 
EvalustloN) Study 
Willem J. Remme, Guenther Riegger, Per Hildebrandt, Michel Komajda, Marco Bobbio, 
Jordi Soler-Soler, Wybren Jaarsma, Stuart Pocock, Lars Ryden, on behalf of the 
CARMEN investigators, Sticares, Rotterdam, The Netherlands 
Background: Treatment guidelines for chronic hean failure (CHF) recommend ACE- 
inhibitor (ACE-I) as first-line treatment and eblcckers are to be added in case patients 
remain symptomatic. This paradigm, based on historical grounds, enforces polyphar- 
macy and prevents an individualized approach to the treatment of CHF. The aims of the 
CARMEN trial were to challenge this paradigm by comparing the effect on cardiac 
remodeling of the ACE-I Enalapril (E) against Carvedilol (C) a combined PI/&- blocker 
with additional a, -receptor blockade and antioxidant properties. 
Methods: CARMEN is a parallel-group, 3.arm, double-dummy, multi-center study con- 
ducted in 13 European countries. Patients were randomized to C&E, C or E treatment, 
uptitrated on C to 25mg (50mg in patients _> 65kg) bid target dose and/or E to 1Omg bid 
target dose, and continued for 16 months. In the C&E treated arm. C was uptitrated first. 
Effects on left ventricular (LV) remodeling were assessed by serial transthoracic 
echocardiography (biplane, Simpson) at baseline, months 6, 12 and 16 at a central core 
laboratory. 
Results: The ITT population included 479 mild (NYHA II = 65%, LV ejection fraction (EF) 
<40%) CHF patients (C&E = 156; C = 161; E = 160), 61% male, mean age 62 years. LV 
end systolic volume index (LVESVI) was reduced by 5.4 ml/m* (p=O.O015), LV end dias- 
tolic volume index by 5.0 ml/m2 (p=O.OOSS) and LVEF increased by 2.3% (p=O.O022) at 
month 16 for the primary comparison favoring C&E versus E. The second primary com- 
parison favored C versus E, although differences were not significant. However, in the 
within-group comparison C significantly reduced LVESVI by 2.6 mVm2 (p=O.O16) corn- 
pared to baseline, whereas no changes were observed in E, and LVESVI decreased by 
6.3 ml/ m2 (p=O.OOOl) in C&E. 
All three arm showed very similar safety profiles and withdrawal rates. 
Conclusion: The CARMEN results confirm the current treatment guidelines and provide 
an immediate mandate for prescribing the combination of ACE-I and C in mild CHF 
patients. However, as C was safely initiated before ACE-I and resulted in reversed LV 
remodeling, one might challenge the historical sequence of ACE-I as first-line therapy 
and start treatment with Carvedilol before ACE-I. 
1085-75 Double Blind, Placebo-Controlled Study of Long-Term 
Intermittent Dobutamine Infusion With Concomitant 
Oral Amiodsrone for End Stage Heart Failure 
Eleftheria Tsagalou, Maria Anastasiou-Nana, George Alexopoulos, John Terrovitis, 
Konstantinos Chalkias, Christos Gialamas, Konstantinos Christodoulou, John Kanakakis, 
John N. Nanas. University of Athens, Athens, Greece 
Background: Agents with positive inotropic affect have consistently been shown to 
increase mortality when administered chronically to patients with congestive heart failure 
(CHF). A non randomized study has showed that long-term intermittent dobutamine infu- 
sion (IDI) combined with oral amiodarone, improves the sumival of patients with end 
stage CHF .The purpose of this randomized double blind study was to evaluate prospec- 
tively the effects of long-term IDI combined with oral amiodarone in patients with CHF, 
refractory to slandard medical treatment. Methods: Thirty patients with decompensated 
CHF refractory to standard treatment were randomized in a double blind manner to 
receive for 6 hours every 14 days intravenous infusion of placebo (Group 1, n=14), or 
dobutamme lOpg/kg/min, (Group 2, n=l6). All patients were treated with oral amio- 
darone, 400mgld, started at least 2 weeks before randomization. Results: There ware 
no differences in baseline clinical, hemodynamic and biochemical characteristics 
between the two groups. The left ventricular ejection fraction was 24 i5 % and 23+6% in 
Group 1 and 2 respectively (~~0.563); mean pulmonary capillary wedge pressure 30*6 
